fbpx

GRUPO DE ONCOLOGÍA MOLECULAR

TECNOLOGÍAS TRASVERSALES
Grupo de Oncología Molecular

PAOLO G. NUCIFORO
Investigator principal
Biosketch

La misión del Grupo de Oncología Molecular del VHIO es aplicar tecnologías de vanguardia basadas en tejidos a la investigación básica, traslacional y clínica con un enfoque claro hacia el desarrollo y validación de nuevos biomarcadores tumorales para la medicina de precisión en oncología.

Junto con el Grupo de Genómica del Cáncer (IP Ana Vivancos) y el Grupo de Ciencia de Datos Oncológicos ODysSey (IP Rodrigo Dienstmann) del VHIO, además de Susana Aguilar y Jenifer González, nuestro grupo participa en el Programa de preselección molecular del VHIO. Determinamos los perfiles moleculares de más de 1100 pacientes cada año como candidatos para su inclusión en ensayos clínicos en fase inicial en nuestra Unidad de Investigación de Terapia Molecular del Cáncer (UITM)-Fundación «la Caixa». También ejercemos como una de las plataformas tecnológicas centrales del VHIO y, por lo tanto, nuestro laboratorio es clave para nuestras líneas y programas de investigación traslacional.

Participamos activamente en todos los proyectos que implican el uso de tejido humano recogido de pacientes, incluidos análisis de biomarcadores para la estratificación de pacientes y la inclusión en ensayos clínicos, patología digital, bancos de tejidos y el desarrollo de modelos primarios de xenoinjertos derivados de pacientes (PDX). Nuestra contribución se refleja en varios artículos colaborativos de alto factor de impacto publicados a lo largo de 2019.

Nuestro grupo también continúa trabajando tanto de forma independiente como en asociación para establecer el impacto del microbioma en el desarrollo y la progresión del cáncer colorrectal. En particular, estamos desarrollando un ensayo de diagnóstico de Fusobacterium nucleatum que permite la visualización y cuantificación simultáneas de bacterias dentro de los tumores.

Como centro de referencia, hemos contribuido a aproximadamente 280 estudios clínicos realizados en Vall d’Hebron, lo que representa alrededor del 70 % de todos los ensayos actualmente en curso en nuestra institución. Nuestra participación en ensayos clínicos abarca desde la coordinación de la recogida, el almacenamiento y el envío de muestras, junto con el desarrollo y ejecución de múltiples ensayos para la inclusión de pacientes en tiempo real, así como la monitorización farmacodinámica y la determinación de la dosis.

En 2019, realizamos más de 4000 determinaciones moleculares en muestras para la inclusión de pacientes en ensayos clínicos y más de 23 000 pruebas para respaldar la investigación básica y traslacional. También hemos actuado como el laboratorio central elegido en 10 estudios internacionales y hemos mantenido con éxito la prestigiosa acreditación ISO 15189 que avala nuestra calidad y competencia.

OBJETIVOS ESTRATÉGICOS

  • Descubrimiento y validación de nuevos biomarcadores usando tecnologías basadas en los tejidos.
  • Identificación de alteraciones susceptibles de selección como parte del Programa de preselección del VHIO.
  • Aplicar estrategias de patología molecular para respaldar los programas de desarrollo de fármacos en fase inicial.
  • Resolver la interacción espacial de la microbiota asociada al tumor, las células tumorales y las células inmunitarias en el microambiente del tumor.
  • Definir mejor la epidemiología de las dianas moleculares para que las estrategias de tratamiento sean más precisas.
  • Actuar como laboratorio central y local en ensayos clínicos.
  • Actuar como centro de referencia para los programas de investigación del VHIO.

ASPECTOS DESTACADOS

  • Aplicación de proteómica multiplexada dirigida para la preselección molecular y el descubrimiento de biomarcadores en el cáncer colorrectal metastásico (Scientific Reports 2019).
  • Líder del paquete de trabajo y laboratorio central para COLOSSUS (Avance de un paradigma de medicina de precisión en el cáncer colorrectal metastásico: sistemas basados en soluciones de estratificación de pacientes), con el apoyo de Horizonte 2020.

EQUIPO

  • Investigador Principal
    • Paolo G. Nuciforo
  • Attending Physicians
    • Roberta Fasani
    • Sara Simonetti
  • Supervisor de laboratorio
    • Jose Antonio Jiménez
  • Asistente de Laboratorio
    • Mª Ángeles Díaz
  • Becarios post-doctorales
    • Francisca Gallego
  •  Estudiante de doctorado
    • Garazi Serna
  •  Técnicos
    • Lidia Alonso
    • Clara Castán
    • Eloy Garcia
    • Xavier Guardia
    • Paola Martínez
    • Stefania Napoli
    • Gertrudis Sánchez
    • Lidia Sánchez Flores
    • César Javier Sevillano
  • Estudiantes
    • Audrey Detolle
    • Esther Farell
    • Kristiana Plamenova

 


Publicaciones científicas más relevantes

  • Saura C, Hlauschek D, Oliveira M, Zardavas D, Jallitsch-Halper A, de la Peña L, Nuciforo P, Ballestrero A, Dubsky P, Lombard JM, Vuylsteke P, Castaneda CA, Colleoni M, Santos Borges G, Ciruelos E, Fornier M, Boer K, Bardia A, Wilson TR, Stout TJ, Hsu JY, Shi Y, Piccart M, Gnant M, Baselga J, de Azambuja E. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2019 Sep;20(9):1226-1238. doi: 10.1016/S1470-2045(19)30334-1.
  • Oliveira M, Saura C, Nuciforo P, Calvo I, Andersen J, Passos-Coelho JL, Gil Gil M, Bermejo B, Patt DA, Ciruelos E, de la Peña L, Xu N, Wongchenko M, Shi Z, Singel SM, Isakoff SJ. FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer. Ann Oncol. 2019 Aug 1;30(8):1289-1297.
  • Nuciforo P, Pascual T, Cortés J, Llombart-Cussac A, Fasani R, Paré L, Oliveira M, Galvan P, Martínez N, Bermejo B, Vidal M, Pernas S, López R, Muñoz M, Garau I, Manso L, Alarcón J, Martínez E, Rodrik-Outmezguine V, Brase JC, Villagrasa P, Prat A, Holgado E. A predictive model of pathologic response based on tumor cellularity and tumor-infiltratinglymphocytes (CelTIL) in HER2- positive breast cancer treated with chemo-free dual HER2 blockade. Ann Oncol. 2018 Jan 1;29(1):170-177.
  • Bullman S, Pedamallu CS, Sicinska E, Clancy TE, Zhang X, Cai D, Neuberg D, Huang K, Guevara F, Nelson T, Chipashvili O, Hagan T, Walker M, Ramachandran A, Diosdado B, Serna G, Mulet N, Landolfi S, Ramon Y Cajal S, Fasani R, Aguirre AJ, Ng K, Élez E, Ogino S, Tabernero J, Fuchs CS, Hahn WC, Nuciforo P, Meyerson M. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science 2017 Dec 15;358(6369):1443-1448. doi: 10.1126/science.aal5240. Epub 2017 Nov 23.
  • Nuciforo P, Pascual T, Cortés J, Llombart-Cussac A, Fasani R, Paré L, Oliveira M, Galvan P, Martínez N, Bermejo B, Vidal M, Pernas S, López R, Muñoz M, Garau I, Manso L, Alarcón J, Martínez E, Rodrik-Outmezguine V, Brase JC, Villagrasa P, Prat A, Holgado E. A predictive model of pathological response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade. Ann Oncol. 2017 Oct 12. doi: 10.1093/annonc/mdx647. [Epub ahead of print].
  • Zabala-Letona A, Arruabarrena-Aristorena A, Martín-Martín N, Fernandez-Ruiz S, Sutherland JD, Clasquin M, Tomas-Cortazar J, Jimenez J, Torres I, Quang P, Ximenez-Embun P, Bago R, Ugalde-Olano A, Loizaga-Iriarte A, Lacasa-Viscasillas I, Unda M, Torrano V, Cabrera D, van Liempd SM, Cendon Y, Castro E, Murray S, Revandkar A, Alimonti A, Zhang Y, Barnett A, Lein G, Pirman D, Cortazar A, Arreal L, Prudkin L, Astobiza I, Valcarcel-Jimenez L, Zuñiga-García P, Fernandez-Dominguez I, Piva M, Caro-Maldonado A, Sánchez-Mosquera P, Castillo-Martín M, Serra V, Beraza N, Gentilella A, Thomas G, Azkargorta M, Elortza F, Farràs R, Olmos D, Efeyan A, Anguita J, Muñoz J, Falcón-Pérez JM, Barrio R, Macarulla T, Mato JM, Martinez-Chantar ML, Cordon-Cardo C, Aransay AM, Marks K, Baselga J, Tabernero J, Nuciforo P, Manning BD, Marjon K, Carracedo A. MTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. Nature. 2017 Jul 6;547(7661):109-113.
  • Llombart-Cussac A, Cortes J, Paré L, Galvan P, Bermejo B, Martínez N, Vidal M, Pernas S, López R, Muñoz M, Nuciforo P, Morales S, Oliveira M, de la Peña L, Peláez A, Prat A. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. Lancet Oncol. 2017 Apr;18(4):545-554. doi: 10.1016/S1470-2045(17)30021-9. Epub 2017 Feb 24.
  • Nuciforo P, Thyparambil S, Aura C, Garrido-Castro A, Vilaro M, Peg V, Jimenez J, Vicario R, Cecchi F, Hoos W, Burrows J, Hembrough T, Ferreres JC, Perez-Garcia J, Arribas J, Cortes J, Scaltriti M. High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy. Mol Oncol. 2016;10(1):138-147.
  • Prat A, Galván P, Jiménez B, Buckingham W, Jeiranian HA, Schaper C, Vidal M, Alvarez M, Díaz S, Ellis C, Nuciforo P, Ferree S, Ribelles N, Adamo B, Ramón y Cajal S, Peg V, Alba E. Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay.Clin. Cancer Res. 2016 Feb; 22(3): 560-6
  • Arqués O, Chicote I, Puig I, Tenbaum SP, Argiles G, Dienstmann R, Fernández N, Caratù G, Matito J, Silberschmidt D, Rodón J, Landolfi S, Prat A, Espín E, Charco R, Nuciforo P, Vivancos A, Shao W, Tabernero J, Pálmer HG. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. Clin. Cancer Res. 2016 Feb; 22(3): 644-56
  • Scaltriti M, Nuciforo P, Bradbury I, Sperinde J, Agbor-Tarh D, Campbell C, Chenna A, Winslow J, Serra V, Parra JL, Prudkin L, Jimenez J, Aura C, Harbeck N, Pusztai L, Ellis C, Eidtmann H, Arribas J, Cortes J, de Azambuja E, Piccart M, Baselga J. High HER2 expression correlates with response to the combination of lapatinib and trastuzumab. Clin. Cancer Res. 2015 Feb; 21(3): 569-76
  • Prudkin L, Nuciforo P. Obstacles to precision oncology: confronting current factors affecting the successful introduction of biomarkers to the clinic. Cell Oncol (Dordr) 2015 Feb; 38(1): 39-48
  • García-García C, Rivas MA, Ibrahim YH, Calvo MT, Gris-Oliver A, Rodriguez O, Grueso J, Anton P, Guzman M, Aura C, Nuciforo P, Jessen K, Argiles G, Dienstmann R, Bertotti A, Trusolino L, Matito J, Vivancos A, Chicote I, Pálmer HG, Tabernero J, Scaltriti M, Baselga J, Serra V. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer. Clin. Cancer Res. 2015 Dec; 21(24): 5499-510
  • Vicario R, Peg V, Morancho B, Zacarias-Fluck M, Zhang J, Martínez-Barriocanal Á, Navarro Jiménez A, Aura C, Burgues O, Lluch A, Cortes J, Nuciforo P, Rubio IT, Marangoni E, Deeds J, Boehm M, Schlegel R, Tabernero J, Mosher R, Arribas J. Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies. PLoS ONE 2015; 10(6): e0129876
  • Salgado R, Denkert C, Campbell C, Savas P, Nuciforo P, Nucifero P, Aura C, de Azambuja E, Eidtmann H, Ellis CE, Baselga J, Piccart-Gebhart MJ, Michiels S, Bradbury I, Sotiriou C, Loi S. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. JAMA Oncol 2015 Jul; 1(4): 448-54
  • Herrero A, Pinto A, Colón-Bolea P, Casar B, Jones M, Agudo-Ibáñez L, Vidal R, Tenbaum SP, Nuciforo P, Valdizán EM, Horváth Z, Orfi L, Pineda-Lucena A, Bony E, Keri G, Rivas G, Pazos A, Gozalbes R, Pálmer HG, Hurlstone A, Crespo P. Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes. Cancer Cell 2015 Aug; 28(2): 170-82
  • Nuciforo P, Radosevic-Robin N, Ng T, Scaltriti M. Quantification of HER family receptors in breast cancer. Breast Cancer Res. 2015; 17: 53Nuciforo P, Thyparambil S, Aura C, Garrido-Castro A, Vilaro M, Peg V, Jimenez J, Vicario R, Cecchi F, Hoos W, Burrows J, Hembrough T, Ferreres JC, Perez-Garcia J, Arribas J, Cortes J, Scaltriti M. High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy. Mol Oncol. 2016;10(1):138-147. Epub 2015 Sep 15.
  • Salgado R, Denkert C, Campbell C, Savas P, Nuciforo P, Aura C, de Azambuja E, Eidtmann H, Ellis CE, Baselga J, Piccart-Gebhart MJ, Michiels S, Bradbury I, Sotiriou C, Loi S. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. JAMA Oncol. 2015;1(4):448-454. Erratum in: JAMA Oncol. 2015;1(8):1172.
  • Nuciforo P, Radosevic-Robin N, Ng T, Scaltriti M. Quantification of HER family receptors in breast cancer. Breast Cancer Res. 2015;17:53.
  • Nuciforo PG, Aura C, Holmes E, Prudkin L, Jimenez J, Martinez P, Ameels H, de la Peña L, Ellis C, Eidtmann H, Piccart-Gebhart MJ, Scaltriti M, Baselga J. Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status. Ann Oncol. 2015;26(7):1494-1500.

Todas las publicaciones

  •  Nuciforo, Paolo Giovanni; Pascual, T; Cortes Castan, Javier; Llombart-Cussac, A; Fasani, Roberta; Paré, L; Antunes de Melo E Oliveira, Mafalda; Galvan Jurado, Patricia; Martínez, N; Bermejo, B; Vidal Losada, Mª Jesús; Pernas, S; López, R; Muñoz, M; Garau, I; Manso, L; Alarcón, J; Martínez, E; Rodrik-Outmezguine, V; Brase, J C; Villagrasa, P; Prat, A; Holgado, E. A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade. Ann Oncol. 2018 Jan 01. Doi: 10.1093/annonc/mdx647.
  • De Mattos Arruda, Leticia; Ng, Charlotte K Y; Piscuoglio, Salvatore; Gonzalez-Cao, Maria; Lim, Raymond S; De Filippo, Maria R; Fusco, Nicola; Schultheis, Anne M; Ortiz, Carolina; Viteri, Santiago; Arias Piñeiro, Alexandra; Macedo, Gabriel S; Antunes de Melo E Oliveira, Mafalda; Gomez Pardo, Patricia; Teixidó, Cristina; Nuciforo, Paolo Giovanni; Peg, Vicente; Saura Manich, Cristina; Ramon Y Cajal, Santiago; Casas, Francesc Tresserra; Weigelt, Britta; Cortes Castan, Javier; Seoane Suarez, Joan; Reis-Filho, Jorge S. Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases. Oncotarget. 2018 Apr 17. Doi: 10.18632/oncotarget.25041.
  • Cruz Zambrano, Cristina; Castroviejo Bermejo, Cristina; Gutierrez Enriquez, Sara Iliana; Llop Guevara, Alba; Ibrahim, Y H; Gris Oliver, Albert; Bonache Real, Sandra; Morancho Armisen, Beatriz; Bruna, A; Rueda, O M; Lai, Z; Polanska, U M; Jones, G N; Kristel, P; de Bustos, L; Guzman, Marta; Rodriguez Ferreiro, Olga; Grueso Gracera, Judit; Montalban Canudas, Gemma; Caratu, Ginevra; Mancuso, Francesco Mattia; Fasani, Roberta; Jimenez, Jose; Howat, W J; Dougherty, B; Vivancos Prellezo, Ana; Nuciforo, Paolo Giovanni; Serres-Créixams, X; Rubio, I T; Oaknin Benzaquen, Ana; Cadogan, E;. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Ann Oncol. 2018 May 18. Doi: 10.1093/annonc/mdy099.
  • Capdevila Castillon, Jaume ; Mayor Ferreras, Regina; Mancuso, Francesco Mattia; Iglesias, C; Caratu, Ginevra; Matos Garcia, Ignacio; Zafón, C; Hernando Cubero, Jorge; Petit, A; Nuciforo, Paolo Giovanni; Cameselle-Teijeiro, J M; Álvarez, C; Recio, J A; Tabernero Caturla, Josep; Matias-Guiu, X; Vivancos Prellezo, Ana; Seoane Suarez, Joa. Early evolutionary divergence between papillary and anaplastic thyroid cancers. Ann Oncol. 2018 June 1. Doi: 10.1093/annonc/mdy123.
  • Allen, W L; Dunne, P D; McDade, S; Scanlon, E; Loughrey, M; Coleman, H; McCann, C; McLaughlin, K; Nemeth, Z; Syed, N; Jithesh, P; Arthur, K; Wilson, R; Coyle, V; McArt, D; Murray, G I; Samuel, L; Nuciforo, Paolo Giovanni; Jimenez Jose; Argiles Martinez, Guillermo; Diesntmann, Rodrigo; Tabernero Caturla, Josep; Messerini, L; Nobili, S; Mini, E; Sheahan, K; Ryan, E; Johnston, P G; Van Schaeybroeck, S; Lawler, M; Longley, D B. Transcriptional subtyping and CD8 immunohistochemistry identifies poor prognosis stage II/III colorectal cancer patients who benefit from adjuvant chemotherapy. JCO Precis Oncol. 2018 June 13. Doi: 10.1200/PO.17.0024.1
  • Saei, Azad; Palafox Sanchez, Marta; Benoukraf, Touati; Kumari, Nishi; Jaynes, Patrick William; Iyengar, Prasanna Vasudevan; Muñoz Couselo, Eva; Nuciforo, Paolo Giovanni; Cortes Castan, Javier; Nötzel, Christopher; Kumarakulasinghe, Nesaretnam Barr; Richard, John Lalith Charles; Bin Adam Isa, Zul Fazreen; Pang, Brendan; Guzman, Marta; Siqin, Zhou; Yang, Henry; Tam, Wai Leong; Serra Elizalde, Violeta; Eichhorn, Pieter Johan Adam. Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies. J Exp Med. 2018 Jul 2 Doi: 10.1084/jem.20171960.
  • Cedres Perez, Susana; Felip Font, Enriqueta; Cruz Zambrano, Cristina; Martinez De Castro, Ana Maria; Pardo Aranda, Nuria; Navarro Mendivil, Alejandro; Martinez Marti, Alexandre; Remon Masip, Jordi; Zeron Medina, Jorge; Balmaña Gelpi, Judith; Llop Guevara, Alba; Miquel Aymar, Josep Maria; Sansano, Irene; Nuciforo, Paolo Giovanni; Mancuso, Francesco Mattia; Serra Elizalde, Violeta; Vivancos Prellezo, Ana. Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation. J Natl Cancer Inst. 2018 August 1. Doi: 10.1093/jnci/djy012.
  • Puig Borreil, Isabel; Tenbaum, Stephan Paul; Chicote Ramos, Irene; Arques Casamitjana, Oriol; Martinez-Quintanilla Martinez, Jordi; Cuesta Borras, Estefania; Ramírez, Lorena; Gonzalo, Pilar; Soto, Atenea; Aguilar, Susana; Eguizabal, Cristina; Caratu, Ginevra; Prat Aparicio, Aleix; Argiles Martinez, Guillermo; Landolfi, Stefania; Casanovas, Oriol; Serra Elizalde, Violeta; Villanueva, Alberto; Arroyo, Alicia G; Terracciano, Luigi; Nuciforo, Paolo Giovanni; Seoane Suarez, Joan; Recio, Juan A; Vivancos Prellezo, Ana; Dienstmann, Rodrigo; Tabernero Caturla, Josep; Garcia Palmer, Hector. TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence. J Natl Cancer Inst. 2018 August 31. Doi: 10.1172/JCI96393.
  • Rius Ruiz, Irene; Vicario, Rocio; Morancho Armisen, Beatriz; Bernado Morales, Cristina; Arenas, Enrique J; Herter, Sylvia; Freimoser-Grundschober, Anne; Somandin, Jitka; Sam, Johannes; Ast, Oliver; Barriocanal, Águeda Martinez; Luque Garcia, Antonio Miguel; Escorihuela Baez, Marta; Varela Tang, Ismael; Cuartas Maza, Mª Isabel; Nuciforo, Paolo Giovanni; Fasani, Roberta; Peg, Vicente; Rubio, Isabel; Cortes Castan, Javier; Serra Elizalde, Violeta; Escriva De Romani Muñoz, Santiago; Sperinde, Jeff; Chenna, Ahmed; Huang, Weidong; Winslow, John; Albanell, Joan; Seoane Suarez, Joan; Scaltriti, Maurizio; Baselga Torres, Josep; Tabernero Caturla, Josep; Umana, Pablo; Bacac, Marina; Saura Manich, Cristina; Klein, Christian; Arribas Lopez, Joaquin Vicente. p95HER2-T cell bispecific antibody for breast cancer treatment. Sci Transl Med. 2018 Oct. 3. Doi: 10.1126/scitranslmed.aat1445.
  • De Mattos Arruda, Leticia; Weigelt, B; Cortes Castan, Javier; Won, H H; Ng, C K Y; Nuciforo, Paolo Giovanni; Bidard, F-C; Aura, C; Saura Manich, Cristina; Peg, V; Piscuoglio, S; Antunes De Melo E Oliveira, Mafalda; Smolders, Y; Patel, P; Norton, L; Tabernero Caturla, Josep; Berger, M F; Seoane Suarez, Joan; Reis-Filho, J S. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. Ann Oncol. 2018 Nov 01. Doi: 10.1093/annonc/mdx804.
  • Powles, Ryan L; Redmond, David; Sotiriou, Christos; Loi, Sherene; Fumagalli, Debora; Nuciforo, Paolo Giovanni; Harbeck, Nadia; De Azambuja, Evandro; Sarp, Severine; Di Cosimo, Serena; Huober, Jens; Baselga Torres, Josep; Piccart-Gebhart, Martine; Elemento, Olivier; Pusztai, Lajos; Hatzis, Christos. Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol. 2018 Nov 01. Doi: 10.1001/jamaoncol.2018.1564.
  • Castroviejo-Bermejo, Marta; Cruz, Cristina; Llop Guevara, Alba; Gutierrez Enriquez, Sara Iliana; Ducy, Mandy; Ibrahim, Yasir Hussein; Gris Oliver, Albert; Pellegrino, Benedetta; Bruna, Alejandra; Guzman, Marta; Rodriguez Ferreiro, Olga; Grueso Gragera, Judit; Bonache, Sandra; Moles-Fernández, Alejandro; Villacampa, Guillermo; Viaplana, Cristina; Gomez Pardo, Patricia; Vidal, Marc; Peg, Vicente; Serres-Créixams, Xavier; Dellaire, Graham; Simard, Jacques; Nuciforo, Paolo Giovanni; Rubio, Isabel T; Dientsmann, Rodrigo; Barrett, J Carl; Caldas, Carlos; Baselga, José; Saura Manich, Cristina; Cortés, Javier; Déas, Olivier; Jonkers, Jos; Masson, Jean-Yves; Cairo, Stefano; Judde, Jean-Gabriel; O’connor, Mark J; Diez Gibert, Orland; Balmaña, Judith; Serra Elizalde, Violeta. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. EMBO Mol Med. 2018 Dec.01 Doi: 10.15252/emmm.201809172.
  • Nuciforo P. The search for simplicity: is this compatible with precision medicine? Ann Oncol 2016. First published online: October 25, 2016 doi: 10.1093/annonc/mdw566.
  • Llombart-Cussac A, Cortés J, Paré L, Galván P, Bermejo B, Martínez N, Vidal M, Pernas S, López R, Muñoz M, Nuciforo P, Morales S, Oliveira M, de la Peña L, Peláez A, Prat A. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. Lancet Oncol. 2017 Apr;18(4):545-554. doi: 10.1016/S1470-2045(17)30021-9. Epub 2017 Feb 24.
  • Cejalvo JM, Martínez de Dueñas E, Galván P, García-Recio S, Burgués Gasión O, Paré L, Antolín S, Martinello R, Blancas I, Adamo B, Guerrero-Zotano Á, Muñoz M, Nucíforo P, Vidal M, Pérez RM, Chacón López-Muniz JI, Caballero R, Peg V, Carrasco E, Rojo F, Perou CM, Cortés J, Adamo V, Albanell J, Gomis RR, Lluch A, Prat A. Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer. Cancer Res. 2017 May 1;77(9):2213-2221. doi: 10.1158/0008-5472.CAN-16-2717. Epub 2017 Mar 1.
  • Grasselli J, Elez E, Caratù G, Matito J, Santos C, Macarulla T, Vidal J, Garcia M, Viéitez JM, Paéz D, Falcó E, Lopez Lopez C, Aranda E, Jones F, Sikri V, Nuciforo P, Fasani R, Tabernero J, Montagut C, Azuara D, Dienstmann R, Salazar R, Vivancos A. Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer. Ann Oncol. 2017 Jun 1;28(6):1294-1301. doi: 10.1093/annonc/mdx112.
  • Prat A, Navarro A, Paré L, Reguart N, Galvan P, Pascual T, Martínez A, Nuciforo P, Comerma L, Alos L, Pardo N, Cedrés S, Fan C, Parker JS, Gaba L, Victoria I, Viñolas N, Vivancos A, Arance A, Felip E. Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma and melanoma. Cancer Res. 2017 May 9. pii: canres.3556.2017. doi: 10.1158/0008-5472.CAN-16-3556. [Epub ahead of print].
  • Dienstmann R, Elez E, Argiles G, Matos I, Sanz-Garcia E, Ortiz C, Macarulla T, Capdevila J, Alsina M, Sauri T, Verdaguer H, Vilaro M, Ruiz-Pace F, Viaplana C, Garcia A, Landolfi S, Palmer HG, Nuciforo P, Rodon J, Vivancos A, Tabernero JAnalysis of mutant allele fractions in driver genes in colorectal cancer – biological and clinical insights. Mol Oncol. 2017 Sep;11(9):1263-1272. doi: 10.1002/1878-0261.12099. Epub 2017 Jul 20.
  • Rodon J, Postel-Vinay S, Hollebecque A, Nuciforo P, Azaro A, Cattan V, Marfai L, Sudey I, Brendel K, Delmas A, Malasse S, Soria JC. First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours. Eur J Cancer. 2017 Aug;81:142-150. doi: 10.1016/j.ejca.2017.05.007.
  • Zabala-Letona A, Arruabarrena-Aristorena A, Martín-Martín N, Fernandez-Ruiz S, Sutherland JD, Clasquin M, Tomas-Cortazar J, Jimenez J, Torres I, Quang P, Ximenez-Embun P, Bago R, Ugalde-Olano A, Loizaga-Iriarte A, Lacasa-Viscasillas I, Unda M, Torrano V, Cabrera D, van Liempd SM, Cendon Y, Castro E, Murray S, Revandkar A, Alimonti A, Zhang Y, Barnett A, Lein G, Pirman D, Cortazar AR, Arreal L, Prudkin L, Astobiza I, Valcarcel-Jimenez L, Zuñiga-García P, Fernandez-Dominguez I, Piva M, Caro-Maldonado A, Sánchez-Mosquera P, Castillo-Martín M, Serra V, Beraza N, Gentilella A, Thomas G, Azkargorta M, Elortza F, Farràs R, Olmos D, Efeyan A, Anguita J, Muñoz J, Falcón-Pérez JM, Barrio R, Macarulla T, Mato JM, Martinez-Chantar ML, Cordon-Cardo C, Aransay AM, Marks K, Baselga J, Tabernero J, Nuciforo P, Manning BD, Marjon K, Carracedo A. mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. Nature. 2017 Jul 6;547(7661):109-113. doi: 10.1038/nature22964. Epub 2017 Jun 28.
  • Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O’Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB. Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Adv Anat Pathol. 2017 Sep;24(5):235-251. doi: 10.1097/PAP.0000000000000162.
  • Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O’Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Adv Anat Pathol. 2017 Nov;24(6):311-335. doi: 10.1097/PAP.0000000000000161.
  • Martinez-Marti A, Felip E, Matito J, Mereu E, Navarro A, Cedrés S, Pardo N, Martinez de Castro A, Remon J, Miquel JM, Guillaumet-Adkins A, Nadal E, Rodriguez-Esteban G, Arqués O, Fasani R, Nuciforo P, Heyn H, Villanueva A, Palmer HG, Vivancos A. Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 2017 Oct 1;28(10):2451-2457. doi: 10.1093/annonc/mdx396.
  • Nuciforo P, Pascual T, Cortés J, Llombart-Cussac A, Fasani R, Paré L, Oliveira M, Galvan P, Martínez N, Bermejo B, Vidal M, Pernas S, López R, Muñoz M, Garau I, Manso L, Alarcón J, Martínez E, Rodrik-Outmezguine V, Brase JC, Villagrasa P, Prat A, Holgado E. A predictive model of pathological response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade. Ann Oncol. 2017 Oct 12. doi: 10.1093/annonc/mdx647. [Epub ahead of print]
  • Bullman S, Pedamallu CS, Sicinska E, Clancy TE, Zhang X, Cai D, Neuberg D, Huang K, Guevara F, Nelson T, Chipashvili O, Hagan T, Walker M, Ramachandran A, Diosdado B, Serna G, Mulet N, Landolfi S, Ramon Y Cajal S, Fasani R, Aguirre AJ, Ng K, Élez E, Ogino S, Tabernero J, Fuchs CS, Hahn WC, Nuciforo P, Meyerson M. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science. 2017 Dec 15;358(6369):1443-1448. doi: 10.1126/science.aal5240. Epub 2017 Nov 23.
  • Prat A, Galván P, Jiménez B, Buckingham W, Jeiranian HA, Schaper C, Vidal M, Alvarez M, Díaz S, Ellis C, Nuciforo P, Ferree S, Ribelles N, Adamo B, Ramón y Cajal S, Peg V, Alba E. Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay.Clin. Cancer Res. 2016 Feb; 22(3): 560-6
  • Arqués O, Chicote I, Puig I, Tenbaum SP, Argiles G, Dienstmann R, Fernández N, Caratù G, Matito J, Silberschmidt D, Rodón J, Landolfi S, Prat A, Espín E, Charco R, Nuciforo P, Vivancos A, Shao W, Tabernero J, Pálmer HG. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. Clin. Cancer Res. 2016 Feb; 22(3): 644-56
  • Scaltriti M, Nuciforo P, Bradbury I, Sperinde J, Agbor-Tarh D, Campbell C, Chenna A, Winslow J, Serra V, Parra JL, Prudkin L, Jimenez J, Aura C, Harbeck N, Pusztai L, Ellis C, Eidtmann H, Arribas J, Cortes J, de Azambuja E, Piccart M, Baselga J. High HER2 expression correlates with response to the combination of lapatinib and trastuzumab. Clin. Cancer Res. 2015 Feb; 21(3): 569-76
  • Prudkin L, Nuciforo P. Obstacles to precision oncology: confronting current factors affecting the successful introduction of biomarkers to the clinic. Cell Oncol (Dordr) 2015 Feb; 38(1): 39-48
  • García-García C, Rivas MA, Ibrahim YH, Calvo MT, Gris-Oliver A, Rodriguez O, Grueso J, Anton P, Guzman M, Aura C, Nuciforo P, Jessen K, Argiles G, Dienstmann R, Bertotti A, Trusolino L, Matito J, Vivancos A, Chicote I, Pálmer HG, Tabernero J, Scaltriti M, Baselga J, Serra V. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer. Clin. Cancer Res. 2015 Dec; 21(24): 5499-510
  • Vicario R, Peg V, Morancho B, Zacarias-Fluck M, Zhang J, Martínez-Barriocanal Á, Navarro Jiménez A, Aura C, Burgues O, Lluch A, Cortes J, Nuciforo P, Rubio IT, Marangoni E, Deeds J, Boehm M, Schlegel R, Tabernero J, Mosher R, Arribas J. Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies. PLoS ONE 2015; 10(6): e0129876
  • Salgado R, Denkert C, Campbell C, Savas P, Nuciforo P, Nucifero P, Aura C, de Azambuja E, Eidtmann H, Ellis CE, Baselga J, Piccart-Gebhart MJ, Michiels S, Bradbury I, Sotiriou C, Loi S. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. JAMA Oncol 2015 Jul; 1(4): 448-54
  • Herrero A, Pinto A, Colón-Bolea P, Casar B, Jones M, Agudo-Ibáñez L, Vidal R, Tenbaum SP, Nuciforo P, Valdizán EM, Horváth Z, Orfi L, Pineda-Lucena A, Bony E, Keri G, Rivas G, Pazos A, Gozalbes R, Pálmer HG, Hurlstone A, Crespo P. Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes. Cancer Cell 2015 Aug; 28(2): 170-82
  • Nuciforo P, Radosevic-Robin N, Ng T, Scaltriti M. Quantification of HER family receptors in breast cancer. Breast Cancer Res. 2015; 17: 53
  • Prat A, Adamo B, Fan C, Peg V, Vidal M, Galván P, Vivancos A, Nuciforo P, Pálmer HG, Dawood S, Rodón J, Cajal SR, Campo JM, Felip E, Tabernero J, Cortes J. ERRATUM: Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity. Sci Rep 2015; 5: 8179
  • Majewski IJ, Nuciforo P, Mittempergher L, Bosma AJ, Eidtmann H, Holmes E, Sotiriou C, Fumagalli D, Jimenez J, Aura C, Prudkin L, Díaz-Delgado MC, de La Peña L, Loi S, Ellis C, Schultz N, de Azambuja E, Harbeck N, Piccart-Gebhart M, Bernards R, Baselga J. PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. J. Clin. Oncol. 2015 Apr; 33(12): 1334-9
  • De Mattos-Arruda L, Bidard FC, Won HH, Cortes J, Ng CK, Peg V, Nuciforo P, Jungbluth AA, Weigelt B, Berger MF, Seoane J, Reis-Filho JS. Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing. Mol Oncol 2014 Feb; 8(1): 150-8
  • Dienstmann R, Rodón J, Prat A, Pérez-García J, Adamo B, Felip E, Cortes J, Iafrate AJ, Nuciforo P, Tabernero J. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann. Oncol. 2014 Mar; 25(3): 552-63
  • Parra-Palau JL, Morancho B, Peg V, Escorihuela M, Scaltriti M, Vicario R, Zacarias-Fluck M, Pedersen K, Pandiella A, Nuciforo P, Serra V, Cortes J, Baselga J, Perou CM, Prat A, Rubio IT, Arribas J. Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy. J. Natl. Cancer Inst. 2014 Nov; 106(11)
  • De Mattos-Arruda L, Weigelt B, Cortes J, Won HH, Ng CK, Nuciforo P, Bidard FC, Aura C, Saura C, Peg V, Piscuoglio S, Oliveira M, Smolders Y, Patel P, Norton L, Tabernero J, Berger MF, Seoane J, Reis-Filho JS. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. Ann. Oncol. 2014 Sep; 25(9): 1729-35
  • Prat A, Adamo B, Fan C, Peg V, Vidal M, Galván P, Vivancos A, Nuciforo P, Pálmer HG, Dawood S, Rodón J, Cajal SR, Ramón y Cajal S, del Campo JM, Ramony Cajal S, Felip E, Tabernero J, Cortes J. Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity. Sci Rep 2013; 3: 3544
  • Belloni B, Lambertini C, Nuciforo P, Phillips J, Bruening E, Wong S, Dummer R. Will PAXgene substitute formalin? A morphological and molecular comparative study using a new fixative system. J. Clin. Pathol. 2013 Feb; 66(2): 124-35
  • Serra V, Vivancos A, Puente XS, Felip E, Silberschmidt D, Caratù G, Parra JL, De Mattos-Arruda L, Grueso J, Hernandez-Losa J, Arribas J, Prudkin L, Nuciforo P, Scaltriti M, Seoane J, Baselga J. Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation. Cancer Discov 2013 Nov; 3(11): 1238-44
  • Lambertini C, Barzaghi-Rinaudo P, D’Amato L, Schulz S, Nuciforo P, Schmid HA. Evaluation of somatostatin receptor subtype expression in human neuroendocrine tumors using two sets of new monoclonal antibodies. Regul. Pept. 2013 Nov; 187: 35-41
  • Lucá R, Averna M, Zalfa F, Vecchi M, Bianchi F, La Fata G, Del Nonno F, Nardacci R, Bianchi M, Nuciforo P, Munck S, Parrella P, Moura R, Signori E, Alston R, Kuchnio A, Farace MG, Fazio VM, Piacentini M, De Strooper B, Achsel T, Neri G, Neven P, Evans DG, Carmeliet P, Mazzone M, Bagni C. The fragile X protein binds mRNAs involved in cancer progression and modulates metastasis formation. EMBO Mol Med 2013 Oct; 5(10): 1523-36
  • Schmid HA, Lambertini C, van Vugt HH, Barzaghi-Rinaudo P, Schäfer J, Hillenbrand R, Sailer AW, Kaufmann M, Nuciforo P. Monoclonal antibodies against the human somatostatin receptor subtypes 1-5: development and immunohistochemical application in neuroendocrine tumors. Neuroendocrinology 2012; 95(3): 232-47
  • Zipser MC, Eichhoff OM, Widmer DS, Schlegel NC, Schoenewolf NL, Stuart D, Liu W, Gardner H, Smith PD, Nuciforo P, Dummer R, Hoek KS. A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status. Pigment Cell Melanoma Res 2011 Apr; 24(2): 326-33
  • Luise C, Capra M, Donzelli M, Mazzarol G, Jodice MG, Nuciforo P, Viale G, Di Fiore PP, Confalonieri S. An atlas of altered expression of deubiquitinating enzymes in human cancer. PLoS ONE 2011; 6(1): e15891
  • Rustighi A, Tiberi L, Soldano A, Napoli M, Nuciforo P, Rosato A, Kaplan F, Capobianco A, Pece S, Di Fiore PP, Del Sal G. The prolyl-isomerase Pin1 is a Notch1 target that enhances Notch1 activation in cancer. Nat. Cell Biol. 2009 Feb; 11(2): 133-42
  • Raynaud CM, Jang SJ, Nuciforo P, Lantuejoul S, Brambilla E, Mounier N, Olaussen KA, André F, Morat L, Sabatier L, Soria JC. Telomere shortening is correlated with the DNA damage response and telomeric protein down-regulation in colorectal preneoplastic lesions. Ann. Oncol. 2008 Nov; 19(11): 1875-81
  • Colaluca IN, Tosoni D, Nuciforo P, Senic-Matuglia F, Galimberti V, Viale G, Pece S, Di Fiore PP. NUMB controls p53 tumour suppressor activity. Nature 2008 Jan; 451(7174): 76-80
  • Vecchi M, Confalonieri S, Nuciforo P, Viganò MA, Capra M, Bianchi M, Nicosia D, Bianchi F, Galimberti V, Viale G, Palermo G, Riccardi A, Campanini R, Daidone MG, Pierotti MA, Pece S, Di Fiore PP. Breast cancer metastases are molecularly distinct from their primary tumors. Oncogene 2008 Apr; 27(15): 2148-58
  • Bianchi F, Nuciforo P, Vecchi M, Bernard L, Tizzoni L, Marchetti A, Buttitta F, Felicioni L, Nicassio F, Di Fiore PP. Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. J. Clin. Invest. 2007 Nov; 117(11): 3436-44
  • Vecchi M, Nuciforo P, Romagnoli S, Confalonieri S, Pellegrini C, Serio G, Quarto M, Capra M, Roviaro GC, Contessini Avesani E, Corsi C, Coggi G, Di Fiore PP, Bosari S. Gene expression analysis of early and advanced gastric cancers. Oncogene 2007 Jun; 26(29): 4284-94